Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)

This top executive at Harmony Biosciences previous sold all of his direct shares in the company in early January 2026. But towards the end of the month, some options and restricted stock units vested, and everything changed.

This bioscience company has had promising financials, yet one of its top executives exited his entire direct equity ownership in mid-January 2026.

This bioscience company has had promising financials, yet one of its top executives exited her entire direct equity ownership in mid-January 2026.

The biotech company is looking for multiple successes in the coming years.

Some investors haven't gotten answers to their questions about the biotech stock's past and future.

But deciding if it's a good buy takes a little more looking.

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three quarters of the year, the rare-disease specialist has encountered a late-year slump, retreating from its 52-week

Harmony Biosciences (HRMY) exemplifies Growth at a Reasonable Price (GARP) with strong sales growth, robust profitability, and a solid financial base, all at a compelling valuation.

Harmony Biosciences (HRMY) presents a classic value investing case with strong profitability, a healthy balance sheet, and solid growth—all at a compellingly low valuation.

Harmony Biosciences (HRMY) is a top GARP stock with strong growth, stellar profitability, and a surprisingly cheap valuation. A compelling growth at a reasonable price pick.

Harmony Biosciences (HRMY) appears undervalued with a low P/E ratio, strong profitability, and impressive growth, suggesting a potential market opportunity.

Harmony Biosciences Q3 2025 earnings beat estimates with strong WAKIX growth. Despite the beat, stock dipped slightly in pre-market trading.

Harmony Biosciences (HRMY) offers strong growth at a reasonable price. With high EPS growth, robust profitability, and a low P/E ratio, it's a top GARP stock.

The curtain has largely fallen on the Q3 2025 earnings season, revealing a financial landscape characterized by robust corporate performance, particularly in the technology and financial sectors, alongside a cautious yet optimistic market sentiment. Companies across the S&P 500 demonstrated notable resilience, with a significant majority surpassing analyst expectations.

Harmony Biosciences (HRMY) is a value stock with a low P/E ratio, strong profitability, a healthy balance sheet, and solid growth potential.

Harmony Biosciences (HRMY) offers strong growth, high profitability, and an attractive valuation. Its positive technical setup suggests a potential breakout, making it a compelling stock to watch.

Harmony Biosciences (HRMY) offers affordable growth with strong EPS & revenue expansion, a low P/E ratio, and robust profitability in rare neurological treatments.

Analysts' ratings for Harmony Biosciences Hldgs (NASDAQ: HRMY) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.